Colchicine for Long COVID: Randomized Trial Finds No Benefit in Functional Recovery or Inflammatory Resolution
Posted inInfectious Diseases Internal Medicine news

Colchicine for Long COVID: Randomized Trial Finds No Benefit in Functional Recovery or Inflammatory Resolution

A multi-center randomized clinical trial published in JAMA Internal Medicine demonstrates that colchicine, despite its potent anti-inflammatory properties, fails to improve 6-minute walk test distances or inflammatory markers in patients suffering from Long COVID, highlighting the complexity of the condition's pathogenesis.
Selenium Supplementation Fails to Improve Remission or Quality of Life in Graves’ Hyperthyroidism: Findings from the GRASS RCT
Posted inDiabetes & Endocrinology Internal Medicine news

Selenium Supplementation Fails to Improve Remission or Quality of Life in Graves’ Hyperthyroidism: Findings from the GRASS RCT

The GRASS trial, a double-blind multi-centre RCT, found that adding 200 µg of selenium daily to standard antithyroid drug therapy does not increase remission rates or improve quality of life in patients with newly diagnosed Graves' hyperthyroidism, suggesting no clinical benefit for routine supplementation.
Repurposing Hydroxychloroquine for Chronic Inflammatory Cardiomyopathy: Evidence from the HYPIC Multicenter Randomized Trial
Posted inCardiology Clinical Updates news

Repurposing Hydroxychloroquine for Chronic Inflammatory Cardiomyopathy: Evidence from the HYPIC Multicenter Randomized Trial

The HYPIC trial demonstrates that hydroxychloroquine combined with prednisolone significantly improves cardiovascular outcomes, cardiac function, and cytokine profiles in patients with chronic inflammatory cardiomyopathy following fulminant myocarditis, establishing a novel evidence-based therapeutic strategy.
Antiviral Therapy Fails to Slow Alzheimer’s: The VALAD Trial Reveals Unexpected Cognitive Worsening with Valacyclovir
Posted inNeurology news Psychiatry

Antiviral Therapy Fails to Slow Alzheimer’s: The VALAD Trial Reveals Unexpected Cognitive Worsening with Valacyclovir

The VALAD randomized clinical trial found that valacyclovir did not improve outcomes in patients with early symptomatic Alzheimer’s and HSV seropositivity. Instead, patients receiving the antiviral showed significantly greater cognitive decline compared to placebo over 78 weeks, cautioning against off-label use.
High-Dose Oral Rifampin Did Not Improve Survival in Tuberculous Meningitis—HARVEST Trial Shows No Benefit and Possible Harm
Posted inInfectious Diseases Neurology news

High-Dose Oral Rifampin Did Not Improve Survival in Tuberculous Meningitis—HARVEST Trial Shows No Benefit and Possible Harm

A multinational randomized trial found that adding high‑dose oral rifampin (total 35 mg/kg for 8 weeks) to standard therapy did not reduce 6‑month mortality in adults with tuberculous meningitis and was associated with more drug‑induced liver injury and earlier deaths in some patients.